Measurable residual disease in acute lymphoblastic leukemia: How low is low enough?
Aaron C. Logan
Abstract
. With additional evidence to facilitate integration of highly sensitive MRD quantification into clinical care and to contextualize MRD within the genotype of individual patients, it will likely be increasingly possible to identify patients able to avoid alloHCT and potentially even de-escalate therapy.
Topics & Concepts
Minimal residual diseaseBlinatumomabMedicineOncologyDiseaseChimeric antigen receptorImmunotherapyHematopoietic stem cell transplantationImmunologyTransplantationLeukemiaDisease burdenInternal medicineIntensive care medicineLymphoblastic LeukemiaImmune systemAcute Lymphoblastic Leukemia researchAcute Myeloid Leukemia ResearchHematopoietic Stem Cell Transplantation